Alvotech SA
ALVO8.810USD
+0.020+0.23%
交易中 （美東）報價延遲15分鐘
2.66B總市值
27.54本益比TTM
關於 Alvotech SA 公司
Alvotech SA 是一家生物技術公司。該公司專注於爲全球患者開發和生產生物仿製藥。該公司致力於開發一系列單克隆抗體，這些抗體針對多種治療領域，包括炎症性疾病、腫瘤學和眼科。該公司的產品線包含八種生物仿製藥候選藥物，旨在治療自身免疫性疾病、眼部疾病、骨質疏鬆症、呼吸系統疾病和癌症。其產品線包括 AVT02、AVT04、AVT23、AVT03、AVT05、AVT06、AVT16 和 AVT33。其 AVT02 是一種單克隆抗體，是 Humira（阿達木單抗）的生物仿製藥。AVT04 是一種單克隆抗體，是 Stelara（烏司奴單抗）的生物仿製藥候選藥物。它已形成一個戰略商業合作伙伴網絡，提供全球覆蓋範圍並利用包括美國、歐洲、日本、中國和其他亞洲國家以及南美洲、非洲和中東大部分地區的市場的專業知識。
公司簡介
公司代碼ALVO
公司名稱Alvotech SA
上市日期Nov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
員工數量1011
證券類型Ordinary Share
年結日Nov 09
公司地址9, Rue De Bitbourg
城市LUXEMBOURG
上市交易所NASDAQ Global Market Consolidated
國家Luxembourg
郵編1273
電話35244224500
網址https://www.alvotech.com/
公司代碼ALVO
上市日期Nov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Mr. Benedikt Stefansson
Mr. Benedikt Stefansson
Director of Investor Relations and Global Communications
Director of Investor Relations and Global Communications
--
--
Ms. Tanya Zharov
Ms. Tanya Zharov
General Counsel
General Counsel
--
--
Mr. Faysal Kalmoua
Mr. Faysal Kalmoua
Chief Operating Officer, Executive Director
Chief Operating Officer, Executive Director
--
--
Mr. Tomas Ekman
Mr. Tomas Ekman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2022
暫無數據
地區USD
名稱
營收
佔比
USA
273.04M
55.76%
Europe
157.59M
32.18%
Rest of the world
59.06M
12.06%
業務
地區
暫無數據
股東統計
更新時間: 5月26日 週一
更新時間: 5月26日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
持股股東
持股股東
佔比
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
股東類型
持股股東
佔比
Corporation
62.99%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
1.94%
Hedge Fund
1.40%
Individual Investor
0.46%
Private Equity
0.43%
Research Firm
0.34%
Other
30.11%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
114
212.07M
69.88%
-4.61M
2025Q1
115
212.60M
70.06%
-4.31M
2024Q4
102
214.30M
71.08%
-114.96K
2024Q3
87
213.88M
70.94%
+661.45K
2024Q2
85
209.20M
73.73%
-4.01M
2024Q1
143
208.53M
73.94%
-24.07M
2023Q4
136
211.95M
80.98%
-21.83M
2023Q3
145
212.41M
81.19%
-22.41M
2023Q2
144
212.79M
81.57%
-23.47M
2023Q1
154
213.81M
82.04%
-23.18M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Aztiq Pharma Partners SARL
101.15M
33.33%
-2.59M
-2.49%
Mar 01, 2025
Celtic Holdings SCA
90.01M
29.66%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
4.19M
1.38%
+995.54K
+31.14%
Mar 31, 2025
Bracebridge Capital, LLC
2.71M
0.89%
--
--
Mar 31, 2025
Oaktree Capital Management, L.P.
1.97M
0.65%
-68.40K
-3.35%
Mar 31, 2025
T. Rowe Price International Ltd
1.40M
0.46%
+1.20M
+587.57%
Mar 31, 2025
Littlejohn & Co. LLC
1.32M
0.43%
--
--
Mar 31, 2025
PointState Capital LP
1.17M
0.39%
-67.04K
-5.40%
Mar 31, 2025
Davies (Richard John)
1.07M
0.35%
+19.71K
+1.88%
Mar 01, 2025
Stefnir hf.
998.47K
0.33%
-10.00K
-0.99%
May 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.27%
iShares Biotechnology ETF
0.1%
Strive Small-Cap ETF
0.04%
Schwab Emerging Markets Equity ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Vanguard Total World Stock Index Fund
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Vanguard FTSE All-World ex-US Index Fund
0%
ProShares Ultra Nasdaq Biotechnology
佔比0.27%
Invesco Nasdaq Biotechnology ETF
佔比0.27%
iShares Biotechnology ETF
佔比0.1%
Strive Small-Cap ETF
佔比0.04%
Schwab Emerging Markets Equity ETF
佔比0.01%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Vanguard Total World Stock Index Fund
佔比0%
First Trust IPOX Europe Equity Opportunities ETF
佔比0%
Vanguard FTSE All-World ex-US Index Fund
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
